Glomerulonephritis Clinical Trials

7 recruiting

Glomerulonephritis Trials at a Glance

27 actively recruiting trials for glomerulonephritis are listed on ClinicalTrialsFinder across 6 cities in 36 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in New York, Prague, and Beijing. Lead sponsors running glomerulonephritis studies include Novartis Pharmaceuticals, Mayo Clinic, and Alexandria University.

Browse glomerulonephritis trials by phase

Treatments under study

About Glomerulonephritis Clinical Trials

Looking for clinical trials for Glomerulonephritis? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Glomerulonephritis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Glomerulonephritis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting
Phase 2

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

Glomerulonephritis, IGAImmunoglobulin A Nephropathy
Novartis Pharmaceuticals20 enrolled18 locationsNCT06797518
Recruiting
Phase 2

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Autoimmune DiseaseProteinuriaGlomerular Disease+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled2 locationsNCT00977977
Recruiting
Phase 2

Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

Fibrillary Glomerulonephritis
Mayo Clinic20 enrolled1 locationNCT06295770
Recruiting
Phase 3

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

C3 GlomerulopathyImmune-complex-membranoproliferative Glomerulonephritis
Novartis Pharmaceuticals225 enrolled50 locationsNCT03955445
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi84 enrolled69 locationsNCT06500702
Recruiting
Not Applicable

Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases

HealthyAtypical Hemolytic Uremic SyndromeMembranoproliferative Glomerulonephritis+1 more
Mario Negri Institute for Pharmacological Research105 enrolled1 locationNCT05996731
Recruiting
Phase 3

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

Kidney DiseasesKidney Diseases, ChronicUrological Diseases+5 more
Novartis Pharmaceuticals220 enrolled6 locationsNCT06858319
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

IgA Nephropathy (IgAN)Membranous NephropathyANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)+2 more
Grit Biotechnology30 enrolled1 locationNCT07389499
Recruiting

The Clinical Application of Artificial Intelligence Assisted Renal Biopsy Diagnosis System.

Chronic Kidney DiseaseChronic Glomerulonephritis
Zhujiang Hospital2,900 enrolled2 locationsNCT07330362
Recruiting
Phase 2

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Glomerulonephritis Rapidly Progressive
Alentis Therapeutics AG80 enrolled49 locationsNCT06047171
Recruiting
Phase 2

Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits

Proliferative Glomerulonephritis With Monoclonal IgG Deposits
Mayo Clinic40 enrolled4 locationsNCT05654506
Recruiting
Phase 2

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

C3 GlomerulopathyIdiopathic Immune Complex-Mediated Glomerulonephritis
Omeros Corporation20 enrolled6 locationsNCT06209736
Recruiting
Phase 4

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

IgA NephropathyRenal Insufficiency, ChronicIgA Vasculitis+1 more
Christian Medical College, Vellore, India585 enrolled12 locationsNCT06676384
Recruiting
Phase 2

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

C3 GlomerulopathyDense Deposit DiseaseMembranoproliferative Glomerulonephritis+2 more
Region Skane30 enrolled4 locationsNCT04183101
Recruiting

AI scribe for clinical documentation

paediatric respiratory conditions e.g. asthmapaediatric neurological conditions including seizuresfailure to thrive.+2 more
Queensland Children's Hospital150 enrolled1 locationACTRN12625000432415
Recruiting

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

Kidney DiseasesDiabetic NephropathyKidney Failure, Chronic+2 more
The Rogosin Institute2,000 enrolled1 locationNCT01802034
Recruiting
Phase 4

Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

GlomerulonephritisImmunoglobulin A Nephropathy
Fondazione Schena878 enrolled2 locationsNCT04662723
Recruiting
Phase 2

Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis

Glomerulonephritis
Alexandria University100 enrolled1 locationNCT06835322
Recruiting
Phase 2

The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland

Kidney FailureParaproteinemiasGlomerulonephritis
Helsinki University Central Hospital30 enrolled1 locationNCT06889948
Recruiting

TESTING -ON Post-Trial ObservatioNal Cohort Study

Kidney DiseasesIgA NephropathyGlomerulonephritis+1 more
The George Institute366 enrolled58 locationsNCT05434325